Octapharma at WFH Congress, June 1 - 5, 2008, Istanbul, Turkey

Octapharma will participate in the Exhibition with 144 sq. ms. booth (#4), presenting our complete coagulation portfolio, including wilate®, octanate®, octanine F®, nanotiv® and octaplex®. Out of a total of 15 scientific posters, which will be displayed at the official poster area, we will have 8 of these put on view on our exhibition booth.

During WFH, Octapharma will proudly present two Satellite Symposia. Please find detailed information below.

The first Symposium entitled “Looking for milestone improvements in VWD treatment – tasks defined and resolved” will address the analytical issues of clinical monitoring of VWF:RCo levels, and explore topics of von Willebrand factor functionality under physiological flow conditions, management of peri-operative hemostasis in VWD patients with wilate®, and the concept of long term prophylaxis in VWD.

The program at a glance: “Looking for milestone improvements in VWD treatment – tasks defined and resolved” – June 3, 2008 , 07.00 – 08.30 to be held in the Lower Ballroom, Hilton  Istanbul Hotel.

• Chairman's introduction: Craig Kessler, Washington
• Monitoring plasma VWF:RCo levels in clinical practice – are all assays the same? - Andreas Hillarp, Malmö
• Functions of VWF under physiological flow conditions– a need to reassess some established beliefs - Christoph Kannicht, Berlin
• Challenges in the management of peri-surgical hemostasis in VWD patients – clinical experience with wilate - Mario von Depka, Hannover and Inge Scharrer, Mainz
• Long term prophylaxis in VWD patients– an evolving concept - Erik Berntorp, Malmö
• Concluding remarks and discussion
  

The second Symposium entitled “Von Willebrand factor in FVIII complex concentrates: from laboratory to clinical practice” will offer a balanced mix of data highlighting the impact of VWF on FVIII-inhibitor immunology, and will provide an opportunity to discuss recent successful interim data from the prospective post-marketing study in progress that support the use of VWF/FVIII concentrate for ITI in haemophilia A patients with poor prognosis.

The program at a glance: “Von Willebrand factor in FVIII complex concentrates: from laboratory to clinical practice” – June 4, 2008, 13.00 – 14.30 in the Lower Ballroom, Hilton Istanbul Hotel.

• Chairman's/Co-chairman's introduction - David Lillicrap, Kingston and Erik Berntorp, Malmö
• Inhibitors in haemophilia A patients with poor prognosis: role of VWF in the immune tolerance
• induction (ITI) - Wolfhart Kreuz, Frankfurt
• Can thrombin generation assay and inhibitor profile help optimise individual ITI treatment?
• Erik Berntorp, Malmö
• Treatment of haemophilia A patients with inhibitors and a poor prognosis in Russia: octanate® ITI
• Nadezhda Zozulya, Moscow
• Treatment of Factor VIII-Inhibitors with octanate® in the UK - Savita Rangarajan, London
• octanate® in ITI: single center experience - Kate Khair, London
• Study of the immunological markers in patients undergoing ITI - Sebastien Lacroix-Desmazes, Paris
• Incidence of FVIII inhibitors in PUPs treated with octanate® - Carmen Escuriola-Ettingshausen, Frankfurt
• Concluding remarks and discussion
  

To learn more about Octapharma products, their characterization and composition, you are invited to participate in our exciting Boxing Challenge or our Walk Around Quiz.

In the Boxing Challenge, you will have to compete against 4 other players in an electronic quiz, which is based on the game “Who wants to be a millionaire”. The player who achieves the highest score can proceed to the electronic boxing match.

The Walk Around Quiz is based on the 8 Posters which are displayed at our booth. The Octapharma Booth Staff will walk you through our booth to assist you in finding the answers to the 8 given questions.

 It is our pleasure to invite you to the Octapharma Booth (Booth No. 4 ) and enjoy a refreshing drink at our Syrup Bar.


.

 © Octapharma AG, 2008